Navigation Links
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Date:8/12/2008

SAN DIEGO, Aug. 12 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held immunotherapeutics discovery and development company focused on the development and commercialization of novel immunotherapies for the treatment of cancer, today announced the completion of two separate licensing agreements with the Memorial Sloan-Kettering Cancer Center's Sloan-Kettering Institute for Cancer Research (SKI).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO)

The first license agreement grants MabVax exclusive development and commercialization rights to multiple vaccines against recurrent cancer for six different types of cancer. MSKCC plans to initiate Phase I clinical trials in each of these types of cancer this year or early next year. Upon successful demonstration of immunogenicity and tolerability in the Phase I trials in sarcoma and small cell lung cancer, MabVax will initiate Phase II trials in these two cancer types. In addition to MabVax's efforts, MSKCC is planning to conduct Phase II trials with the licensed vaccines in ovarian and breast cancer. Pending successful outcomes, MabVax can assume responsibility for continued development and eventual commercialization of these vaccines.

The second license agreement grants MabVax exclusive rights to the use of the licensed vaccines and lymphocytes from successfully vaccinated clinical trial participants. MabVax plans to rescue antibodies from these patient samples to create a pipeline of fully human monoclonal antibody products against each of the vaccine targets expressed on the surface of the cancer cells. By rescuing antibodies from a selection of patients who generate a useful immune response, MabVax can select the optimal antibodies and develop them as either stand alone products or as combination products with the vaccines. MabVax has established a laboratory and office in the San Diego area to launch this effort.

"The completion of these two agreements establishes the scientific foundation of the company and firmly set us on a research and development pathway that we hope will address a significant unmet medical need by preventing recurrence in certain types of cancers and prolonging patient survival," said David Hansen, the company's President and Chief Executive Officer. Philip Livingston, M.D., the company's Chief Science Officer and co-founder of MabVax added, "Targeting residual circulating cancer cells and micrometastasis with passively administered or vaccine induced antibodies against multiple targets is an approach well suited to eradicating the cancer cells that cause metastatic disease. Our clinical trials over the next several years will tell us a great deal about the utility of this approach to treating cancer."

About MabVax Therapeutics, Inc.

MabVax was formed to commercialize the work of Dr. Phil Livingston and colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC) who over the last 25 years have developed monovalent cancer vaccines against ten distinct antigenic targets on various types of cancer cells. These vaccines target gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. Vaccines, or passively administered antibodies developed from these vaccines, produced evidence demonstrating the prevention of tumor recurrence and prolonged survival in preclinical models and supporting data in early Phase I human clinical trials. The company is initially focused on developing polyvalent vaccines and a pipeline of fully human monoclonal antibodies to address a variety of cancers including sarcoma, small cell lung cancer, and melanoma. MabVax closed a Series A venture financing with GBP Capital in late February 2008.


'/>"/>
SOURCE MabVax Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 14, 2017  ivWatch LLC, a medical device company ... (IV) therapy, is pleased to announce it was the ... Hospital Supplies and Equipment at the 2017 Medical Design ... medtech industry. The award was presented by Medical Device ... Center in New York during ...
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the ... President of R&D and Head of Virology Kristin Bedard has ... the Northwest and Beyond meeting sponsored by Life Science ... from 8:30-10:30 AM PDT at the Agora Conference Center in ... Bedard will be joined by other leaders in infectious disease ...
Breaking Medicine Technology:
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the leader in ... position of Executive Vice President, Sales and Marketing. Finnegan is a widely known ... device sales leadership. He has received industry recognition for innovations and new approaches ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands ... whether they can trust the sponsor to pay them correctly and on time. As ... CROs establish payment strategies that encourage sites to work on their studies. , At ...
(Date:6/27/2017)... ... June 27, 2017 , ... Salucro, the ... the health care industry’s hospitals and provider groups, has announced that it will ... customers. Parasail Health is a San Francisco health-finance startup that has launched a ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Association’s SUNucate efforts, Louisiana became the sixth state to pass legislation which ... Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, ...
(Date:6/27/2017)... Beverly Hills, California (PRWEB) , ... June 27, 2017 , ... ... implants market has been projected to reach a staggering $6.81 billion by the year ... implants are rising at a faster rate than those made from titanium. Los Angeles ...
Breaking Medicine News(10 mins):